SCNI
Scinai·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Stock Price Surged Significantly
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SCNI
Scinai Immunotherapeutics Ltd.
A biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses
Pharmaceutical
07/22/2003
05/12/2015
NASDAQ Stock Exchange
31
12-31
Depository Receipts (Ordinary Shares)
Jerusalem BioPark
, 2nd floor
, Hadassah Ein Kerem Campus
, Jerusalem
, Israel
--
Scinai Immunotherapeutics Ltd., established in Israel on July 22, 2003, is a private company. The Company is a biopharmaceutical company focused on the development, manufacture and commercialization of innovative inflammation and immunology (I & I) biological products primarily for the treatment of autoimmune and infectious diseases. With advanced biopharmaceutical product development and manufacturing facilities and experienced pharmaceutical industry leadership, Scinai provides end-to-end boutique CDMO services while developing its own diverse and commercially viable pipeline of products and platforms for diseases with a large number of unmet medical needs.
Company Financials
EPS
SCNI has released its 2024 Q3 earnings. EPS was reported at 0, versus the expected 0, meeting expectations. The chart below visualizes how SCNI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SCNI has released its 2024 Q4 earnings report, with revenue of 206.00K, reflecting a YoY change of NaN%, and net profit of -2.23M, showing a YoY change of 4.29%. The Sankey diagram below clearly presents SCNI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
